| Formulation | Structure | Tolerability | Key Note |
|---|---|---|---|
| AmB Deoxycholate | Micellar suspension | Highest nephrotoxicity; infusion reactions common | Sodium-load before each dose; lowest cost |
| Liposomal AmB | Small unilamellar liposomes | Best tolerated; lowest nephrotoxicity | Preferred when cost is not limiting |
| AmB Lipid Complex | Ribbon-like bilayer structures | Moderate; higher than liposomal AmB | High liver/spleen/lung uptake via phagocytes |
| AmB Colloidal Disp. | Cholesteryl sulfate disks | Highest infusion reaction rate | Rarely chosen; approved for refractory cases |
Use a lipid formulation from the start (do not begin with amphotericin B deoxycholate) when any of the following are present: baseline creatinine above 2.5 mg/dL, concurrent nephrotoxins that cannot be stopped, solid organ or stem cell transplant recipient, or anticipated treatment duration beyond two weeks. Switching after nephrotoxicity develops is suboptimal because tubular damage is cumulative.